FDA Approves Bepirovirsen for Chronic Hepatitis B Suppression
A newly cleared antisense therapy offers measurable viral clearance for chronic hepatitis B, altering long-term liver risk tracking and diagnostic monitoring protocols.
The US Food and Drug Administration cleared bepirovirsen injection for adults with chronic hepatitis B virus infection who do not have cirrhosis, administered alongside standard nucleoside or nucleotide analogues. The decision marks the first regulatory clearance for an antisense oligonucleotide directed at this condition. Rather than indefinitely suppressing viral replication alone, the compound targets viral RNA to prompt clearance of hepatitis B surface antigen (HBsAg).
The clearance rests on clinical data demonstrating sustained loss of HBsAg and undetectable viral DNA after a defined 24-week treatment course. In phase 2b trials published in The New England Journal of Medicine in 2022, approximately 9 to 10 percent of participants receiving the planned dose maintained undetectable antigen levels six months after ending therapy. Standard nucleoside analogues, while protective against liver decompensation, yield functional cure rates below 2 to 3 percent after years of daily dosing.
Predicting which individuals clear antigen remains computationally difficult. Liver health monitoring protocols are shifting from open-ended observation toward discrete, time-bound biological targets. When patients complete finite courses of targeted therapies, secondary prevention turns to automated serology screening and liver stiffness telemetry.
If you manage viral hepatitis or monitor elevated liver enzymes, request your quantitative surface antigen numbers alongside standard viral DNA assays. Knowing your baseline values lets you track immunological response directly rather than assuming ongoing suppression equates to clearance.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.